Biocept is dedicated to supporting its partners, collaborators, and clients with our unique CNSide™ CSF-TC and cfDNA technology platforms for rare event detection and genetic characterization. Our CLIA-licensed and CAP-accredited laboratory combines a highly trained professional staff who are experienced in assay development with innovative instrumentation for optimal test results and quality control.
Our CNSide™ platforms provide flexibility for developing assays with unique requirements for our partners. This development can be performed in our CLIA laboratory. We focus on providing high-level, personalized service to our clients, addressing critical questions of interest to them including:
- Assay development
- Patient population profiling
- Determination of patient eligibility/stratification for clinical trials
- Measuring efficacy endpoints
- Correlative science studies
Please contact Clinical Affairs for more information at 888.332.7729 or via email at email@example.com.